We are live on ! Find out more
VBIO

Valion Bio
VBIO

3 hedge funds and large institutions have $30K invested in Valion Bio in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

25% less funds holding

Funds holding: 4 → 3 (-1)

71% less capital invested

Capital invested by funds: $104K → $30K (-$74K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$6.76K
2
UBS Group
UBS Group
Switzerland
+$3.38K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$73K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
1
Osaic Holdings
Arizona
$13K – – –
TRCT
2
Tower Research Capital (TRC)
New York
$11K +$6.76K +2 +67%
UBS Group
3
UBS Group
Switzerland
$6K +$3.38K +1 +100%
Renaissance Technologies
4
Renaissance Technologies
New York
– -$73K -22 Closed

VBIO Hedge Fund Activity: Q3 2022 in Review

3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q3 2022, worth a combined $30K — down 71% from $104K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of VBIO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $6.76K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $73K sold.

  • 3 institutional investors held Valion Bio (VBIO) as of Q3 2022, down from 4 in Q2 2022.
  • Funds reported $30K of Valion Bio stock for Q3 2022, down 71% quarter-over-quarter.
  • 0 funds opened new Valion Bio positions in Q3 2022 and 1 closed out, a net change of -1 holder.
  • The largest Valion Bio buyer in Q3 2022 was Tower Research Capital (TRC), an estimated $6.76K added.
  • The largest Valion Bio seller in Q3 2022 was Renaissance Technologies, an estimated $73K sold.

Based on aggregated 13F filings for Q3 2022.